Replacement Director/PDMR Shareholding

RNS Number : 5341X

GlaxoSmithKline PLC

08 February 2013

 



This announcement replaces the original announcement released on 2 January 2013 at 16.43 (RNS No: 7101U).

One of the Non-Executive Director's interests in Ordinary Shares of GlaxoSmithKline plc, indicated with an asterix (*) below, was incorrectly stated in the announcement made on 2 January 2013.

Save as disclosed above, all other details remain unchanged. The full amended text is shown below.

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.

On 31 December 2012, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary Shares and American Depositary Shares (ADSs) in the Company through the annual reinvestment of dividends paid throughout 2012:  

GlaxoSmithKline Non-Executive Directors Automatic Share Award and Elected Share Award - Annual Dividend Reinvestment

Non-Executive Director	No. of Ordinary Shares	Average Price (£)	No. of ADSs	Average Price ($)
Sir Christopher Gent	4,610.092	13.43
Prof Sir Roy Anderson	671.657	13.43
Dr Stephanie Burns			549.830	43.39
Ms Stacey Cartwright	67.351	13.43
Sir Crispin Davis	3,835.178	13.43
Ms Judy Lewent			41.107	43.39
Sir Deryck Maughan			1,460.014	43.39
Dr Daniel Podolsky			971.294	43.39
Mr Tom de Swaan	993.381	13.43
Sir Robert Wilson	1,070.610*	13.43

The Company and the Non-Executive Directors were informed of these allocations on 2 January 2013.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

8 February 2013

 

END

 

 

RDSFMGGZVRKGFZM